ImmunoCellular Therapeutics Financials

ImmunoCellular Therapeutics Stock Summary

ImmunoCellular Therapeutics competes with Northwest Biotherapeutics, Catalyst Pharmaceuticals, Pharming Group, Cellectar Biosciences, and Bolt Biotherapeutics. Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey. Immunocellular Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.

ImmunoCellular Therapeutics Key Financial Ratios

ImmunoCellular Therapeutics' financial ratios allow both analysts and investors to convert raw data from ImmunoCellular Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of ImmunoCellular Therapeutics over time and compare it to other companies across industries.

ImmunoCellular Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining ImmunoCellular Therapeutics's current stock value. Our valuation model uses many indicators to compare ImmunoCellular Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ImmunoCellular Therapeutics competition to find correlations between indicators driving ImmunoCellular Therapeutics's intrinsic value. More Info.ImmunoCellular Therapeutics is rated fifth overall in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value ImmunoCellular Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ImmunoCellular Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

ImmunoCellular Therapeutics Market Pulse

Along with financial statement analysis, the daily predictive indicators of ImmunoCellular Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ImmunoCellular Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of ImmunoCellular Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing ImmunoCellular Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ImmunoCellular Therapeutics's daily price indicators and compare them against related drivers.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.